ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

FUM Futura Medical Plc

32.90
-0.05 (-0.15%)
01 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.05 -0.15% 32.90 32.90 33.45 33.50 32.95 33.50 188,398 16:35:02
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -5.85M -0.0194 -16.98 99.08M
Futura Medical Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FUM. The last closing price for Futura Medical was 32.95p. Over the last year, Futura Medical shares have traded in a share price range of 24.10p to 67.00p.

Futura Medical currently has 300,712,293 shares in issue. The market capitalisation of Futura Medical is £99.08 million. Futura Medical has a price to earnings ratio (PE ratio) of -16.98.

Futura Medical Share Discussion Threads

Showing 19876 to 19885 of 21425 messages
Chat Pages: Latest  797  796  795  794  793  792  791  790  789  788  787  786  Older
DateSubjectAuthorDiscuss
24/7/2023
11:31
Hahahaha! Only someone under LiarBOoth's thrall would make that interpretation!

The FACT is, I did call it exactly right, because the 'placebo' (Dermasys) did score very highly in P3, and therefore the trial was deemed a failure. Unfortunately Futura chose to use Dermasys as the placebo without realising its potential as an ED treatment, so in fact it wasn't a proper placebo at all. It eventually went on to become Eroxon, and as Futura have stated, Dermasys has a unique formulation for every application. Therefore LiarBOoth, or any of his accolytes, don't have a shred of proof to call Eroxon a placebo.

petroc
24/7/2023
11:13
LOL! LBO is beating up petroc good n proper but he keeps coming back for more! So funny! :D
thebutler
24/7/2023
09:02
LiarBOoth, thanks for reminding us of this, again!:

'petroc - 06 Nov 2019 - 13:22:07 - 6320 of 17459
The fly in the ointment is the possible high level of positive reaction to placebo'.

Yes, I called that exactly right in the run up to P3. There was a bit of a frenzy due to the 19 out of 20 possibilities of success which was being touted, and people were betting the farm on it, much like you did when CSD500 was released.

So thanks for pointing out that I have a good track record when it comes to predicting FUM, unlike you and your pathetic stock bashing and investing more than you could afford to lose, and then compounding your schoolboy error by selling at the bottom of the market.

So who should people listen to - the lying stock basher who has never called this right, or Petroc who is doing alright, thank you very much

petroc
24/7/2023
07:47
At last an LBO post which actually addresses something someone has said, rather than his constantly repeated 'messages'.I am happy to stand by my 'could be in the 70s' comment.It's just a question of timing. Looking forward to a steady incline upwards.
ajmace
23/7/2023
22:22
You clearly have difficulty in understanding the concept of 'proven', LiarBOoth. You bandy the word around as if it were true, but nearly every time you use it, 'conjecture' would be the word you should have chosen. But that's what you do - twist and manipulate facts into lies, because you are a lying stock basher.
petroc
23/7/2023
20:58
Nobody takes any notice of LBO 1
ajmace
23/7/2023
17:17
'Yet again another proven attempt at 'bias and fraud' by a group of connected multi-ID stock bashers who have incentivised to post 'fraud' by 'fantastic financial incentives' and who bash the stock because they lost money on it previously.



Bias and Fraud

There are numerous biases in medical research that render evidence from such research systematically misleading. Some of these biases are exacerbated by conflicts of interest, including fantastic financial incentives. The most important biases in medical research include confirmation bias, design bias, analysis bias, and publication bias. Arguably, some forms of bias, such as publication bias, should be considered as fraud

petroc
23/7/2023
17:13
You clearly have difficulty in understanding the concept of 'proven', LiarBOoth. You bandy the word around as if it were true, but nearly every time you use it, 'conjecture' would be the word you should have chosen. But that's what you do - twist and manipulate facts into lies, because you are a lying stock basher.
petroc
23/7/2023
16:42
And by the way, Eroxon is definitely not a placebo. FACT! You're clearly thinking of a version of Dermasys which was used in P3 as a placebo, before they realised it worked on its own.
petroc
23/7/2023
16:11
See what I mean?
joestalin
Chat Pages: Latest  797  796  795  794  793  792  791  790  789  788  787  786  Older

Your Recent History

Delayed Upgrade Clock